Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K. Paik, Xiuning Le, Enriqueta Felip et al.|New England Journal of Medicine|2020Cited by 879
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi‐Long Wu, Tae Min Kim, Cheng Huang et al.|The Lancet Oncology|2024Cited by 98
Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHNLisa Licitra, Ricard Mesı́a, F. Rolland et al.|Journal of Clinical Oncology|2009Cited by 22
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 SkippingXiuning Le, John V. Heymach, Lingzhi Hong et al.|JCO Precision Oncology|2021Cited by 21
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort BXiuning Le, Paul K. Paik, Luis Paz‐Ares et al.|Cell Reports Medicine|2023Cited by 18